{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:22:51Z","timestamp":1793395371414,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["734719"],"award-info":[{"award-number":["734719"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["722619"],"award-info":[{"award-number":["722619"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","award":["DSB.AD003.061"],"award-info":[{"award-number":["DSB.AD003.061"]}],"id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.coph.2020.10.016","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T06:33:36Z","timestamp":1606890816000},"page":"165-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-8750","authenticated-orcid":false,"given":"Sara","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.10.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.coph.2020.10.016_sbref0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2020.10.016_bib0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S2213-8587(16)00082-6","article-title":"Phenotypes of prediabetes and stratification of cardiometabolic risk","volume":"4","author":"Stefan","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.coph.2020.10.016_sbref0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.coph.2020.10.016_bib0025","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.coph.2020.10.016_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"Alsahli","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.coph.2020.10.016_bib0035","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1136\/gutjnl-2019-319745","article-title":"Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease","volume":"69","author":"Vily-Petit","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.016_bib0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/diabetes.49.3.450","article-title":"Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation","volume":"49","author":"Joseph","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0045","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2003-031941","article-title":"Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis","volume":"89","author":"Gastaldelli","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2020.10.016_bib0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.29465","article-title":"Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance","volume":"67","author":"Gaggini","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2020.10.016_bib0055","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.016_bib0060","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9994","article-title":"Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease","volume":"7","author":"Hyotylainen","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2020.10.016_bib0065","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2337\/dbi18-0025","article-title":"Insulin action research and the future of diabetes treatment: the 2017 Banting medal for scientific achievement lecture","volume":"67","author":"Accili","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0070","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2337\/db07-0714","article-title":"Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis","volume":"57","author":"Valenti","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.10.016_bib0080","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.cmet.2019.03.014","article-title":"Pyruvate-carboxylase-mediated anaplerosis promotes antioxidant capacity by sustaining TCA cycle and redox metabolism in liver","volume":"29","author":"Cappel","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.10.016_bib0085","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.29025","article-title":"Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"65","author":"McCommis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2020.10.016_bib0090","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_sbref0095","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2020.10.016_bib0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.clpt.6100034","article-title":"Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes","volume":"81","author":"Gastaldelli","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2020.10.016_sbref0105","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1172\/JCI136756","article-title":"Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.10.016_bib0110","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2337\/db15-1373","article-title":"Hepatic and extrahepatic insulin clearance are differentially regulated: results from a novel model-based analysis of intravenous glucose tolerance data","volume":"65","author":"Polidori","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0115","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2337\/db17-0046","article-title":"Opposite regulation of insulin sensitivity by dietary lipid versus carbohydrate excess","volume":"66","author":"Lundsgaard","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0120","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00125-005-1915-z","article-title":"Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice","volume":"48","author":"Ahren","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.10.016_bib0125","doi-asserted-by":"crossref","first-page":"R639","DOI":"10.1152\/ajpregu.00181.2017","article-title":"Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors","volume":"314","author":"Tura","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.coph.2020.10.016_sbref0130","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00125-020-05157-w","article-title":"Insulin sensitivity depends on the route of glucose administration","volume":"63","author":"Mingrone","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.10.016_sbref0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2337\/dc18-1036","article-title":"Insulin clearance after oral and intravenous glucose following gastric bypass and gastric banding weight loss","volume":"42","author":"Shah","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2020.10.016_bib0140","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2337\/db13-1307","article-title":"Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass","volume":"63","author":"Bojsen-Moller","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2337\/dc11-1383","article-title":"Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy","volume":"35","author":"Dunn","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2020.10.016_bib0150","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1172\/JCI64895","article-title":"Gastric bypass and banding equally improve insulin sensitivity and beta cell function","volume":"122","author":"Bradley","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2020.10.016_bib0155","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00125-011-2193-6","article-title":"Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes","volume":"54","author":"Camastra","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.10.016_bib0160","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2337\/dc15-2823","article-title":"Short-term effects of laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass","volume":"39","author":"Gastaldelli","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2020.10.016_bib0165","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2337\/db18-0539","article-title":"Hepatic insulin clearance in regulation of systemic insulin concentrations-role of carbohydrate and energy availability","volume":"67","author":"Bojsen-Moller","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_sbref0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2018.08.001","article-title":"Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice","volume":"88","author":"Villa-Perez","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.coph.2020.10.016_sbref0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2019.01.008","article-title":"Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis","volume":"93","author":"Ghadieh","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.coph.2020.10.016_bib0180","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1152\/physiol.00048.2018","article-title":"Hepatic insulin clearance: mechanism and physiology","volume":"34","author":"Najjar","year":"2019","journal-title":"Physiology"},{"key":"10.1016\/j.coph.2020.10.016_bib0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","article-title":"Beta-cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study","volume":"47","author":"Gastaldelli","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.10.016_bib0190","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1210\/jc.2014-1515","article-title":"The disposition index does not reflect beta-cell function in IGT subjects treated with pioglitazone","volume":"99","author":"DeFronzo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2020.10.016_sbref0195","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1111\/liv.14556","article-title":"Mechanisms for increased risk of diabetes in chronic liver diseases","volume":"40","author":"Svegliati-Baroni","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.coph.2020.10.016_bib0200","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00125-012-2738-3","article-title":"Direct effect of GLP-1 infusion on endogenous glucose production in humans","volume":"56","author":"Seghieri","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.10.016_bib0205","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2015.11.031","article-title":"Time for glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?","volume":"64","author":"Gastaldelli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2020.10.016_sbref0210","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel Dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2020.10.016_bib0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.10.016_sbref0220","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cmet.2018.07.003","article-title":"Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery","volume":"28","author":"Taylor","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.10.016_bib0225","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2020.10.016_bib0230","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1194\/jlr.M086405","article-title":"Fatty liver disrupts glycerol metabolism in gluconeogenic and lipogenic pathways in humans","volume":"59","author":"Jin","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2020.10.016_bib0235","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s42255-020-0222-9","article-title":"The small intestine shields the liver from fructose-induced steatosis","volume":"2","author":"Jang","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.coph.2020.10.016_sbref0240","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cmet.2020.05.012","article-title":"Deletion of fructokinase in the liver or in the intestine reveals differential effects on sugar-induced metabolic dysfunction","volume":"32","author":"Andres-Hernando","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.10.016_sbref0245","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ajcn\/nqz271","article-title":"Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects","volume":"111","author":"Smajis","year":"2020","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.coph.2020.10.016_sbref0250","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2337\/dc17-1318","article-title":"Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis","volume":"41","author":"Apostolopoulou","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2020.10.016_bib0255","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1053\/j.gastro.2012.03.003","article-title":"Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects","volume":"142","author":"Magkos","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.016_bib0260","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.coph.2020.10.016_sbref0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cmet.2018.09.013","article-title":"Protein kinase C epsilon deletion in adipose tissue, but not in liver, improves glucose tolerance","volume":"29","author":"Brandon","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.10.016_sbref0270","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.aav3722","article-title":"Targeting a ceramide double bond improves insulin resistance and hepatic steatosis","volume":"365","author":"Chaurasia","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.coph.2020.10.016_bib0275","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cmet.2015.06.007","article-title":"Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis","volume":"22","author":"Xia","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.coph.2020.10.016_bib0280","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1194\/jlr.M052977","article-title":"Hepatic insulin resistance in ob\/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation","volume":"56","author":"Sajan","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2020.10.016_bib0285","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00125-015-3634-4","article-title":"Hepatokines: unlocking the multi-organ network in metabolic diseases","volume":"58","author":"Iroz","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.coph.2020.10.016_bib0290","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.2337\/db08-0538","article-title":"Plasma fetuin-A levels and the risk of type 2 diabetes","volume":"57","author":"Stefan","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0295","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/diacare.29.02.06.dc05-1484","article-title":"Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects","volume":"29","author":"Mori","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coph.2020.10.016_bib0300","doi-asserted-by":"crossref","first-page":"E266","DOI":"10.1152\/ajpendo.00262.2017","article-title":"The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans","volume":"314","author":"Peter","year":"2018","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.coph.2020.10.016_bib0305","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/dmrr.1177","article-title":"Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity","volume":"27","author":"Mashili","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.coph.2020.10.016_bib0310","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.coph.2020.10.016_bib0315","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:54:47Z","timestamp":1761461687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489220301193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":63,"alternative-id":["S1471489220301193"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.016","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}